Plus   Neg

KAZ Minerals H1 Profit Down

Copper producer KAZ Minerals Plc (KAZ.L), formerly Kazakhmys PLC, reported that its net profit attributable to equity holders of the company for the first half of 2019 declined to $227 million from last year's $276 million, mainly due to the decrease in operating profit in the current period. Earnings per share were $0.47, down from $0.62 in the prior year.

Operating profit for the period decreased to $410 million from the previous year's $464 million, mainly driven by the decrease in revenues.

EBITDA declined 10% to $620 million due to the decrease in revenues which was mainly price driven and from higher cash costs associated with additional volumes, partly offset by the favourable impact on costs of the weaker tenge versus the prior year comparative period.

Revenues for the period were $1.052 billion, a decrease of $46 million from the prior year comparative period, as higher copper volumes from Aktogay and gold volumes from Bozshakol were offset by the impact of lower copper (-11%), gold (-1%), silver (-9%) and zinc (-16%) prices and lower zinc volumes (9.5 kt) from the East Region operations.

Copper revenues decreased from $902 million in the first half of 2018 to $849 million in the current period due to the impact of lower LME prices partly offset by higher copper volumes.

Copper production in the first half increased by 6% to 148 thousand tonnes from last year, as the Aktogay sulphide concentrator ramped up output during the period.

The Group's gold production of 88 thousand ounces in the first half, compared to 90 thousand ounce in the prior year. It is on track to achieve full year guidance of 170-185 thousand ounces, following strong output from Bozymchak for the period and higher volumes expected from the Bozshakol mine over the remainder of the year.

The Board has declared an interim dividend of 4.0 US cents per share in respect of the first half of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world. Humanscale Corp. recalled about 24,900 units of QuickStand Lite workstations for concerns of injury hazard. These include about 2,200 units sold in Canada. The recalled workstation's arm can break and cause the workstation to fall, posing a risk of injury. The company has already received 52 reports of the arm breaking, including 12 reports of minor injuries. Facebook has revealed more details on the structure of an independent "oversight board" that will make final decisions about what posts stay up or come down, even if the company disagrees. The new "Oversight Board" will govern appeals from both Facebook and its users.
Follow RTT